

US clears Alembic's seizure drug

Ahmedabad, May 2

Vadodara-based drug maker Alembic Pharmaceuticals has informed that the company has received final approval from the US drug regulator - US Food and Drug Administration (USFDA) for its lacosamide tablets, which is indicated as adjunctive therapy in patients with partial onset seizures. A statement issued by the company mentioned that the US FDA-approved company's Abbreviated New Drug Application (ANDA) for lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg. "The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Vimpat Tablets of UCB Inc," it said. OUR BUREAU

Company